38 results on '"Frikke-Schmidt, Ruth"'
Search Results
2. Inflammatory response after prehospital high-dose glucocorticoid to patients resuscitated from out-of-hospital cardiac arrest: A sub-study of the STEROHCA trial
- Author
-
Obling, Laust E.R., Beske, Rasmus P., Meyer, Martin A.S., Grand, Johannes, Wiberg, Sebastian, Damm-Hejmdal, Anders, Bjerre, Mette, Frikke-Schmidt, Ruth, Folke, Fredrik, Møller, Jacob E., Kjaergaard, Jesper, and Hassager, Christian
- Published
- 2024
- Full Text
- View/download PDF
3. APOE and vascular disease: Sequencing and genotyping in general population cohorts
- Author
-
Rasmussen, Katrine L., Luo, Jiao, Nordestgaard, Børge G., Tybjærg-Hansen, Anne, and Frikke-Schmidt, Ruth
- Published
- 2023
- Full Text
- View/download PDF
4. Kinetics of cardiac troponin and other biomarkers in patients with ST elevation myocardial infarction
- Author
-
Henrik Kristensen, Jonas, Amalie Wistisen Koczulab, Clara, Anton Frandsen, Emil, Bo Hasselbalch, Rasmus, Strandkjær, Nina, Jørgensen, Nicoline, Østergaard, Morten, Hasse Møller-Sørensen, Peter, Christian Nilsson, Jens, Afzal, Shoaib, Rørbæk Kamstrup, Pia, Dahl, Morten, Bor, Mustafa Vakur, Frikke-Schmidt, Ruth, Rye Jørgensen, Niklas, Rode, Line, Holmvang, Lene, Kjærgaard, Jesper, Evi Bang, Lia, Forman, Julie, Dalhoff, Kim, Bundgaard, Henning, and Karmark Iversen, Kasper
- Published
- 2023
- Full Text
- View/download PDF
5. Plasma TSH and cardiovascular disease in the general population: A Mendelian randomization study of 105,224 individuals
- Author
-
Dalila, Nawar, Frikke-Schmidt, Ruth, Nordestgaard, Børge G., and Tybjærg-Hansen, Anne
- Published
- 2023
- Full Text
- View/download PDF
6. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
- Author
-
Heftdal, Line Dam, Pérez-Alós, Laura, Hasselbalch, Rasmus Bo, Hansen, Cecilie Bo, Hamm, Sebastian Rask, Møller, Dina Leth, Pries-Heje, Mia, Fogh, Kamille, Gerstoft, Jan, Grønbæk, Kirsten, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Sabin, Caroline, and Nielsen, Susanne Dam
- Published
- 2023
- Full Text
- View/download PDF
7. Association between primary care electrocardiogram markers and Alzheimer's disease
- Author
-
Isaksen, Jonas L., Ghouse, Jonas, Skov, Morten W., Olesen, Morten S., Holst, Anders G., Pietersen, Adrian, Nielsen, Jonas B., Maier, Anja, Graff, Claus, Gerds, Thomas A., Frikke-Schmidt, Ruth, and Kanters, Jørgen K.
- Published
- 2023
- Full Text
- View/download PDF
8. Self-reported and genetically predicted coffee consumption and smoking in dementia: A Mendelian randomization study
- Author
-
Nordestgaard, Ask T., Nordestgaard, Børge G., Frikke-Schmidt, Ruth, Juul Rasmussen, Ida, and Bojesen, Stig E.
- Published
- 2022
- Full Text
- View/download PDF
9. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders
- Author
-
Ottesen, Ninja Meinhard, Meluken, Iselin, Frikke-Schmidt, Ruth, Plomgaard, Peter, Scheike, Thomas, Kessing, Lars Vedel, Miskowiak, Kamilla, and Vinberg, Maj
- Published
- 2020
- Full Text
- View/download PDF
10. High body mass index, intermediate metabolic risk factors, and risk of vascular-related dementia: Observational and genetic studies
- Author
-
Nordestgaard, Liv, Luo, Jiao, Emanuelsson, Frida, Christoffersen, Christina, Nordestgaard, Børge, Benn, Marianne, Afzal, Shoaib, Tybjærg-Hansen, Anne, and Frikke-Schmidt, Ruth
- Published
- 2024
- Full Text
- View/download PDF
11. Cardiovascular diseases and risk of dementia in the general population
- Author
-
Luo, Jiao, Rasmussen, Ida Juul, Nordestgaard, Børge, Tybjærg-Hansen, Anne, Thomassen, Jesper, and Frikke-Schmidt, Ruth
- Published
- 2024
- Full Text
- View/download PDF
12. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
- Author
-
Holm-Yildiz, Sonja, Dysgaard, Tina, Krag, Thomas, Pedersen, Britt Stævnsbo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Nielsen, Susanne Dam, and Vissing, John
- Published
- 2023
- Full Text
- View/download PDF
13. Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe
- Author
-
Parini, Paolo, Frikke-Schmidt, Ruth, Tselepis, Alexandros D., Moulin, Philippe, von Eckardstein, Arnold, Binder, Christoph J., Catapano, Alberico L., Ray, Kausik K., and Tokgözoğlu, Lale
- Published
- 2021
- Full Text
- View/download PDF
14. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.
- Author
-
Wilson, Peter W.F., Jacobson, Terry A., Martin, Seth S., Jackson, Elizabeth J., Le, N-Anh, Davidson, Michael H., Vesper, Hubert W., Frikke-Schmidt, Ruth, Ballantyne, Christie M., and Remaley, Alan T.
- Subjects
CARDIOVASCULAR disease prevention ,TRIGLYCERIDES ,HDL cholesterol ,LDL cholesterol ,HYPERCHOLESTEREMIA ,SEVERITY of illness index ,HYPERLIPIDEMIA ,APOLIPOPROTEINS ,CORONARY artery disease ,LIPIDS ,DISEASE risk factors - Abstract
• It is acceptable to screen with nonfasting lipids. • It is recommended to follow up abnormal results with fasting levels. • Non-HDL cholesterol levels can effectively guide ASCVD prevention. • Advanced lipoprotein tests may guide therapeutic decisions in select patients. • Better harmonization of advanced lipid measurement methods is needed. • Recommendations for lipids in clinical care. Lipoprotein measurements are pivotal in the management of patients at risk for atherosclerotic coronary heart disease (CHD) with myocardial infarction and coronary death as the main outcomes, and for atherosclerotic cardiovascular disease (ASCVD), which includes CHD and stroke. Recent developments and changes in guidelines affect optimization of using lipid measures as cardiovascular biomarkers. This scientific statement reviews the pre-analytical, analytical, post-analytical, and clinical aspects of lipoprotein measurements. Highlights include the following: i) It is acceptable to screen with nonfasting lipids. ii) non-high-density lipoprotein HDL-cholesterol (non-HDL-C) is measured reliably in either the fasting or the nonfasting state and can effectively guide ASCVD prevention. iii) low density lipoprotein cholesterol (LDL-C) can be estimated from total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglyceride (TG) measurements. For patients with LDL-C>100 mg/dL and TG ≤150 mg/dL it is reasonable to use the Friedewald formula. However, for those with TG 150-400 mg/dL the Friedewald formula for LDL-C estimation is less accurate. The Martin/Hopkins method is recommended for LDL-C estimation throughout the range of LDL-C levels and up to TG levels of 399 mg/dL. For TG levels ≥400 mg/dL LDL-C estimating equations are currently not recommended and newer methods are being evaluated. iv) When LDL-C or TG screening results are abnormal the clinician should consider obtaining fasting lipids. v) Advanced lipoprotein tests using apolipoprotein B (apoB), LDL Particle Number (LDL-P) or remnant cholesterol may help to guide therapeutic decisions in select patients, but data are limited for patients already on lipid lowering therapy with low LDL-C levels. Better harmonization of advanced lipid measurement methods is needed. Lipid measurements are recommended 4-12 weeks after a change in lipid treatment. Lipid laboratory reports should denote desirable values and specifically identify extremely elevated LDL-C levels (≥190 mg/dL at any age or ≥160 mg/dL in children) as severe hypercholesterolemia. Potentially actionable abnormal lipid test results, including fasting triglycerides (TG) ≥500 mg/dL, should be reported as hypertriglyceridemia. Appropriate use and reporting of lipid tests should improve their utility in the management of persons at high risk for ASCVD events. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. HDL cholesterol and apolipoprotein A-I concentrations and risk of atherosclerotic cardiovascular disease: Human genetics to unravel causality
- Author
-
Frikke-Schmidt, Ruth
- Published
- 2020
- Full Text
- View/download PDF
16. Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease
- Author
-
Qayyum, Faiza, Lauridsen, Bo, Frikke-Schmidt, Ruth, Nordestgaard, Børge, and Tybjærg-Hansen, Anne
- Published
- 2017
- Full Text
- View/download PDF
17. Genetic variation in WRN and ischemic stroke: General population studies and meta-analyses.
- Author
-
Christoffersen, Mette, Frikke-Schmidt, Ruth, Nordestgaard, Børge G., and Tybjærg-Hansen, Anne
- Subjects
- *
STROKE , *CEREBROVASCULAR disease risk factors , *META-analysis , *CLINICAL trials , *HYPOTHESIS , *CONFIDENCE intervals - Abstract
Background Werner syndrome, a premature genetic aging syndrome, shares many clinical features reminiscent of normal physiological aging, and ischemic vascular disease is a frequent cause of death. We tested the hypothesis that genetic variation in the WRN gene was associated with risk of ischemic vascular disease in the general population. Methods We included 58,284 participants from two general population cohorts, the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS). Of these, 6,312 developed ischemic vascular disease during follow-up. In the CCHS ( n = 10,250), we genotyped all non-synonymous variants in WRN with reported minor allele frequencies ≥ 0.5% in Caucasians. Second, variants which were associated with ischemic vascular disease in the CCHS or in previous studies, were genotyped in the CGPS ( n = 48,034). Results A total of 11 non-synonymous variants were identified in the CCHS. In C1367R (rs1346044) TT homozygotes versus CC/CT, hazard ratios for ischemic stroke were 1.09 (95% confidence interval: 0.95–1.24; P = 0.22) in the CCHS, 1.16 (1.00–1.33; P = 0.04) in the CGPS, and 1.12 (1.01–1.23; P = 0.02) in studies combined (CCHS + CGPS), with similar trends for ischemic cerebrovascular disease ( P = 0.06). In meta-analyses including 59,190 individuals in 5 studies, the hazard ratio for ischemic stroke for C1367R TT homozygotes versus CC/CT was 1.14 (1.04–1.25; P = 0.008). Conclusions This study suggests that common genetic variation in WRN is associated with increased risk of ischemic stroke in the general population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Associations between primary care electrocardiography and non-Alzheimer dementia.
- Author
-
Isaksen, Jonas L., Ghouse, Jonas, Skov, Morten W., Olesen, Morten S., Holst, Anders G., Pietersen, Adrian, Nielsen, Jonas B., Maier, Anja, Graff, Claus, Frikke-Schmidt, Ruth, and Kanters, Jørgen K.
- Abstract
Objectives: To determine whether electrocardiogram (ECG) markers are associated with incident non-Alzheimer's dementia (non-AD) and whether these markers also improve risk prediction for non-AD.Materials and Methods: We retrospectively included 170,605 primary care patients aged 60 years or older referred for an ECG by their general practitioner and followed them for a median of 7.6 years. Using Cox regression, we reported hazard ratios (HRs) for electrocardiogram markers. Subsequently, we evaluated if addition of these electrocardiogram markers to a clinical model improved risk prediction for non-AD using change in area under the receiver-operator characteristics curve (AUC).Results: The 5-year cumulative incidence of non-AD was 3.4 %. Increased heart rate (HR=1.06 pr. 10 bpm [95% confidence interval: 1.04-1.08], p<0.001), shorter QRS duration (HR=1.07 pr. 10 ms [1.05-1.09], p<0.001), elevated J-amplitude (HR=1.16 pr. mm [1.08-1.24], p<0.001), decreased T-peak amplitude (HR=1.02 pr. mm [1.01-1.04], p=0.002), and increased QTc (HR=1.08 pr. 20 ms [1.05-1.10], p<0.001) were associated with an increased rate of non-AD. Atrial fibrillation on the ECG (HR=1.18 [1.08-1.28], p<0.001) Sokolow-Lyon index > 35 mm (HR=1.31 [1.18-1.46], p<0.001) and borderline (HR=1.18 [1.11-1.26], p<0.001) or abnormal (HR=1.40 [1.27-1.55], p<0.001) QRS-T angle were also associated with an increased rate of non-AD. Upon addition of ECG markers to the Cox model, 5-year and 10-year C-statistic (AUC) improved significantly (delta-AUC, 0.36 [0.18-0.50] and 0.20 [0.03-0.35] %-points, respectively).Conclusions: ECG markers typical of an elevated cardiovascular risk profile were associated with non-AD and improved both 5-year and 10-year risk predictions for non-AD. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease.
- Author
-
Holmes, Michael V., Frikke-Schmidt, Ruth, Melis, Daniela, Luben, Robert, Asselbergs, Folkert W., Boer, Jolanda M.A., Cooper, Jackie, Palmen, Jutta, Horvat, Pia, Engmann, Jorgen, Li, Ka-Wah, Onland-Moret, N. Charlotte, Hofker, Marten H., Kumari, Meena, Keating, Brendan J., Hubacek, Jaroslav A., Adamkova, Vera, Kubinova, Ruzena, Bobak, Martin, and Khaw, Kay-Tee
- Subjects
- *
GENOTYPES , *ODDS ratio , *META-analysis , *COHORT analysis , *CONFIDENCE intervals , *SMOKING , *HEALTH , *CORONARY heart disease risk factors - Abstract
Background Conflicting evidence exists on whether smoking acts as an effect modifier of the association between APOE genotype and risk of coronary heart disease (CHD). Methods and results We searched PubMed and EMBASE to June 11, 2013 for published studies reporting APOE genotype, smoking status and CHD events and added unpublished data from population cohorts. We tested for presence of effect modification by smoking status in the relationship between APOE genotype and risk of CHD using likelihood ratio test. In total 13 studies (including unpublished data from eight cohorts) with 10,134 CHD events in 130,004 individuals of European descent were identified. The odds ratio (OR) for CHD risk from APOE genotype (ε4 carriers versus non-carriers) was 1.06 (95% confidence interval (CI): 1.01, 1.12) and for smoking (present vs. past/never smokers) was OR 2.05 (95%CI: 1.95, 2.14). When the association between APOE genotype and CHD was stratified by smoking status, compared to non-ε4 carriers, ε4 carriers had an OR of 1.11 (95%CI: 1.02, 1.21) in 28,789 present smokers and an OR of 1.04 (95%CI 0.98, 1.10) in 101,215 previous/never smokers, with no evidence of effect modification ( P -value for heterogeneity = 0.19). Analysis of pack years in individual participant data of >60,000 with adjustment for cardiovascular traits also failed to identify evidence of effect modification. Conclusions In the largest analysis to date, we identified no evidence for effect modification by smoking status in the association between APOE genotype and risk of CHD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. The ABCG5/8 Cholesterol Transporter and Myocardial Infarction Versus Gallstone Disease.
- Author
-
Stender, Stefan, Frikke-Schmidt, Ruth, Nordestgaard, Børge G., and Tybjærg-Hansen, Anne
- Subjects
- *
CHOLESTEROL in the body , *ATP-binding cassette transporters , *MYOCARDIAL infarction , *GALLSTONES , *GENETIC polymorphisms , *MYOCARDIAL infarction risk factors - Abstract
Objectives: The study sought to test the hypothesis that genetic variation in ABCG5/8, the transporter responsible for intestinal and hepatobiliary cholesterol efflux, may simultaneously influence plasma and biliary cholesterol levels, and hence risk of myocardial infarction (MI) and gallstone disease in opposite directions. Background: High plasma levels of low-density lipoprotein (LDL) cholesterol are a causal risk factor for MI, whereas high levels of biliary cholesterol promote gallstone formation. Methods: A total of 60,239 subjects from Copenhagen were included, including 5,647 with MI and 3,174 with symptomatic gallstone disease. Subjects were genotyped for 6 common, nonsynonymous and functional variants in ABCG5/8, and a combined weighted genotype score was calculated. Results: Combined, weighted genotype scores were associated with stepwise decreases in LDL cholesterol of up to 5.9% (0.20 mmol/l) for individuals with a score ≥8.0 (prevalence = 11%) versus <2.0 (prevalence = 9%; p for trend across 5 groups = 2 × 10E-35). The cumulative incidences of MI and gallstone disease as a function of age and increasing genotype score were decreased and increased (log-rank ps for trend: 6 × 10E-4 and 9 × 10E-45), respectively. The multifactorially adjusted odds ratios were 0.83 (95% confidence interval: 0.73 to 0.94) for MI and 2.85 (95% confidence interval: 2.39 to 3.39) for symptomatic gallstone disease for individuals with a genotype score ≥8.0 versus <2.0. Conclusions: Genetic variation in ABCG5/8, which associates with decreased levels of plasma LDL cholesterol protects against MI, but increases the risk of symptomatic gallstone disease. These results suggest that MI and gallstones, 2 seemingly unrelated diseases, are intrinsically linked via the function of the ABCG5/8 cholesterol transporter. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Low-density lipoprotein cholesterol and risk of gallstone disease: A Mendelian randomization study and meta-analyses
- Author
-
Stender, Stefan, Frikke-Schmidt, Ruth, Benn, Marianne, Nordestgaard, Børge G., and Tybjærg-Hansen, Anne
- Subjects
- *
LOW density lipoproteins , *CHOLESTEROL , *GALLSTONES , *RANDOMIZATION (Statistics) , *META-analysis , *HUMAN genetic variation , *DISEASES - Abstract
Background & Aims: Drugs which reduce plasma low-density lipoprotein cholesterol (LDL-C) may protect against gallstone disease. Whether plasma levels of LDL-C per se predict risk of gallstone disease remains unclear. We tested the hypothesis that elevated LDL-C is a causal risk factor for symptomatic gallstone disease. Methods: We used a Mendelian randomization approach and genotyped 63,051 individuals from a prospective cohort study of the general Danish population, including 3323 subjects with symptomatic gallstones. We selected eight genetic variants in APOE, APOB, LDLR, and PCSK9 affecting LDL-C. Furthermore, studies of APOE rs429358/rs7412 (defining ε2/ε3/ε4 alleles; 12 studies) and APOB rs693 (eight studies) were included in meta-analyses. Results: The observational hazard ratio (HR) for symptomatic gallstone disease for the fifth versus first quintile of LDL-C was 0.94 (95% confidence interval: 0.76–1.17), despite a corresponding 134% increase in LDL-C. Furthermore, although individual genetic variants in APOE, APOB, LDLR, and PCSK9 associated with stepwise increases/decreases in LDL-C of up to +59% compared with non-carriers (p <0.001), none predicted the risk of symptomatic gallstone disease. Combining all variants into 10 genotypes, carriers of 9 versus ⩽3 LDL-C increasing alleles associated with 41% increased LDL-C (p <0.001), but predicted a HR for symptomatic gallstone disease of 1.09 (0.70–1.69). Finally, in meta-analyses, random effects odds ratios for gallstone disease were 0.91 (0.78–1.06) for carriers of APOE ε4 versus non-carriers, and 1.25 (0.95–1.63) for APOB rs693 CT+TT versus CC. Conclusions: Results from the observational study, genetic studies, and meta-analyses suggest that elevated plasma levels of LDL-C are not causally associated with increased risk of symptomatic gallstone disease. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
- Author
-
Johannsen, Trine Holm, Frikke-Schmidt, Ruth, Schou, Jesper, Nordestgaard, Børge G., and Tybjærg-Hansen, Anne
- Subjects
- *
CHOLESTERYL ester transfer protein , *GENETIC regulation , *ISCHEMIA , *VASCULAR diseases , *HUMAN genetic variation , *TORCETRAPIB , *SINGLE nucleotide polymorphisms , *ADVERSE health care events - Abstract
Objectives: This study tested whether genetic variation in the CETP gene is consistent with a protective effect of cholesteryl ester transfer protein (CETP) inhibition on risk of ischemic events and on total mortality, without the adverse effects reported for torcetrapib. Background: Torcetrapib, an inhibitor of CETP, increased risk of death and ischemic cardiovascular disease of those randomized to the drug, despite improving the lipid profile. Methods: The Copenhagen City Heart Study is a prospective cohort study of 10,261 individuals, aged 20 to 93 years, who were followed for up to 34 years (1976 to 2010). Of these, 2,087 developed ischemic heart disease, 1,064 developed ischemic cerebrovascular disease, and 3,807 died during follow-up. We selected 2 common genetic variants in CETP previously associated with reductions in CETP activity, thus mimicking the effect of pharmacological CETP inhibition. Results: In individuals carrying 4 versus 0 high-density lipoprotein cholesterol–increasing alleles, there was an increase in levels of high-density lipoprotein cholesterol of up to 14% (0.2 mmol/l), and concomitant decreases in triglycerides, low-density lipoprotein cholesterol, and non–high-density lipoprotein cholesterol of, respectively, 6% (0.1 mmol/l), 3% (0.1 mmol/l), and 4% (0.2 mmol/l) (p for trend 0.004 to <0.001). Corresponding hazard ratios were 0.76 (95% confidence interval [CI]: 0.68 to 0.85) for any ischemic vascular event, 0.74 (95% CI: 0.65 to 0.85) for ischemic heart disease, 0.65 (95% CI: 0.54 to 0.79) for myocardial infarction, 0.77 (95% CI: 0.65 to 0.93) for ischemic cerebrovascular disease, 0.71 (95% CI: 0.58 to 0.88) for ischemic stroke, and 0.88 (95% CI: 0.80 to 0.97) for total mortality. CETP genotypes did not associate with variation in markers of possible side effects previously reported for torcetrapib. Conclusions: Genetic CETP inhibition associates with reductions in risk of ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, and ischemic stroke, with a corresponding antiatherogenic lipid profile, and with increased longevity, without adverse effects. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
23. Common clinical practice versus new PRIM score in predicting coronary heart disease risk
- Author
-
Frikke-Schmidt, Ruth, Tybjærg-Hansen, Anne, Schnohr, Peter, Jensen, Gorm B., and Nordestgaard, Børge G.
- Subjects
- *
CORONARY heart disease risk factors , *HIGH density lipoproteins , *CHOLESTEROL , *BLOOD pressure , *DIABETES , *DISEASES in women , *HYPERTENSION - Abstract
Abstract: Objectives: To compare the new Patient Rule Induction Method (PRIM) Score and common clinical practice with the Framingham Point Score for classification of individuals with respect to coronary heart disease (CHD) risk. Methods and results: PRIM Score and the Framingham Point Score were estimated for 11,444 participants from the Copenhagen City Heart Study. Gender specific cumulative incidences and 10 year absolute CHD risks were estimated for subsets defined by age, total cholesterol, high-density lipoprotein (HDL) cholesterol, blood pressure, diabetes and smoking categories. PRIM defined seven mutually exclusive subsets in women and men, with cumulative incidences of CHD from 0.01 to 0.22 in women, and from 0.03 to 0.26 in men. PRIM versus Framingham Point Score found 11% versus 4% of all women, and 31% versus 35% of all men to have 10 year CHD risks>20%. Among women≥65 years with hypertension and/or with diabetes, 10 year CHD risk>20% was found for 100% with PRIM scoring but for only 18% with the Framingham Point Score. Conclusion: Compared to the PRIM Score, common clinical practice with the Framingham Point Score underestimates CHD risk in women, especially in women≥65 years with hypertension and/or with diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
24. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population
- Author
-
Frikke-Schmidt, Ruth
- Subjects
- *
HUMAN genetic variation , *ATP-binding cassette transporters , *HIGH density lipoproteins , *CHOLESTEROL , *CORONARY heart disease risk factors , *DEMOGRAPHIC research , *EPIDEMIOLOGY - Abstract
Abstract: Epidemiological studies consistently demonstrate a strong inverse association between low levels of high-density lipoprotein (HDL) cholesterol and increased risk of ischemic heart disease (IHD). This review focuses on whether both rare and common genetic variation in ABCA1 contributes to plasma levels of HDL cholesterol and to risk of IHD in the general population, and further seeks to understand whether low levels of HDL cholesterol per se are causally related to IHD. Studies of the ABCA1 gene demonstrate a general strategy for detecting functional genetic variants, and show that both common and rare ABCA1 variants contribute to levels of HDL cholesterol and risk of IHD in the general population. The association between ABCA1 variants and risk of IHD appears, however, to be independent of plasma levels of HDL cholesterol. With the recent identification of the largest number of individuals heterozygous for loss-of-function mutations in ABCA1 worldwide, population studies suggests that genetically low HDL cholesterol per se does not predict an increased risk of IHD, and thus questions the causality of isolated low levels of HDL cholesterol for the development of IHD. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
25. High-throughput genotyping of copy number variation in Glutathione S-Transferases M1 and T1 using real-time PCR in 20,687 individuals
- Author
-
Nørskov, Marianne S., Frikke-Schmidt, Ruth, Loft, Steffen, and Tybjærg-Hansen, Anne
- Subjects
- *
GLUTATHIONE , *POLYMERASE chain reaction , *TRANSFERASES , *NUCLEIC acids - Abstract
Abstract: Objectives: Characteristic for the genes encoding glutathione S-transferase (GST) M1 and GSTT1 is a null allele, suggested to increase susceptibility to chronic diseases. We report an optimized method for the determination of copy number variation (CNV) in GST genes. Design and methods: Real-time multiplex PCR reactions were optimized for quantification of GSTM1 and GSTT1 CNV using the ΔC t method, a fixed volume of diluted DNA, a total volume of 10 μL, 384-well formats, and single determinations of each sample. Results: Consistent genotyping was obtained using DNA in a range of 0.41 ng to 100 ng. In a general population sample of 20,687 individuals the genotype frequencies were concordant with other methods used as standards. Throughput was 4600 genotypes per day at a reagent price of 0.5 euros per sample. Conclusions: This high-throughput, low cost method accurately determines CNV in the GST genes enabling reliable estimates of disease prediction in large epidemiological samples. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
26. Functional Promoter Variant in Zinc Finger Protein 202 Predicts Severe Atherosclerosis and Ischemic Heart Disease
- Author
-
Stene, Maria C.A., Frikke-Schmidt, Ruth, Nordestgaard, Børge G., Grande, Peer, Schnohr, Peter, and Tybjærg-Hansen, Anne
- Subjects
- *
ZINC-finger proteins , *GENETIC polymorphisms , *HEART diseases , *CORONARY disease - Abstract
Objectives: This study was designed to test the hypotheses that single nucleotide polymorphisms (SNPs), in zinc finger protein 202 (ZNF202), predict severe atherosclerosis and ischemic heart disease (IHD). Background: ZNF202 is a transcriptional repressor controlling promoter elements in genes involved in vascular maintenance and lipid metabolism. Methods: We first determined genotype association for 9 ZNF202 SNPs with severe atherosclerosis (ankle brachial index >0.7 vs. ≤0.7) in a cross-sectional study of 5,355 individuals from the Danish general population. We then determined genotype association with IHD in 10,431 individuals from the Danish general population, the CCHS (Copenhagen City Heart Study), including 1,511 incident IHD events during 28 years of follow-up. Results were verified in 2 independent case-control studies including, respectively, 942 and 1,549 cases with IHD and 8,998 controls. Finally, we determined whether g.−660A>G altered transcriptional activity of the ZNF202 promoter in vitro. Results: Cross-sectionally, ZNF202 g.−660 GG versus AA homozygosity predicted an odds ratio for severe atherosclerosis of 2.01 (95% confidence interval [CI]: 1.34 to 3.01). Prospectively, GG versus AA homozygosity predicted a hazard ratio for IHD of 1.21 (95% CI: 1.02 to 1.43). In the 2 case-control studies, the equivalent odds ratios for IHD were 1.29 (95% CI: 1.02 to 1.62) and 1.60 (95% CI: 1.34 to 1.92), confirming the results from the prospective study. Only 2 other SNPs, which were highly correlated with g.−660A>G, also predicted risk of severe atherosclerosis and IHD. Finally, ZNF202 g.−660G versus g.−660A was associated with a 60% reduction in transcriptional activity in vitro, whereas none of the 2 correlated SNPs were predicted to be functional. Conclusions: Homozygosity for a common functional promoter variant in ZNF202 predicts severe atherosclerosis and an increased risk of IHD. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
27. Zinc Finger Protein 202: A new candidate gene for ischemic heart disease: The Copenhagen City Heart Study
- Author
-
Stene, Maria C.A., Frikke-Schmidt, Ruth, Nordestgaard, Børge G., Steffensen, Rolf, Schnohr, Peter, and Tybjærg-Hansen, Anne
- Subjects
- *
ZINC-finger proteins , *CORONARY disease , *MYOCARDIAL infarction , *LIPOPROTEINS - Abstract
Abstract: Objective: Zinc Finger Protein 202 (ZNF202) is a transcriptional repressor of genes affecting the vascular endothelium as well as lipid metabolism. A phenotype associated with genetic variation in ZNF202 is presently unknown. We tested the hypothesis that a common variant in ZNF202, A154V, predicts risk of ischemic heart disease (IHD), myocardial infarction (MI), and ischemic cerebrovascular disease (ICVD). Methods and results: We conducted a prospective study of more than 9000 individuals from the general population with 24 years follow-up. In women, age-adjusted hazard ratios in heterozygotes and homozygotes versus non-carriers were 1.2 (95% CI: 1.0–1.5, P =0.04) and 1.5 (1.1–2.1, P =0.007) for IHD, 1.5 (1.1–2.1; P =0.01) and 1.7 (1.1–2.8, P =0.02) for MI, and 1.3 (1.0–1.8, P =0.07) and 1.3 (0.8–2.1; P =0.33) for ICVD. Adjustments for lipids and lipoproteins did not alter these hazard ratios substantially. Genotype did not predict risk in men. Finally, results for IHD were borderline significant (P =0.06) in an independent case–control study including 933 patients and 8068 controls. Conclusion: This is the first study to suggest that ZNF202 could be a new candidate gene for IHD and MI in the general population. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
28. Mutation in ABCA1 Predicted Risk of Ischemic Heart Disease in the Copenhagen City Heart Study Population
- Author
-
Frikke-Schmidt, Ruth, Nordestgaard, Børge G., Schnohr, Peter, Steffensen, Rolf, and Tybjærg-Hansen, Anne
- Subjects
- *
HEART diseases , *ISCHEMIA , *CYSTIC fibrosis , *ENDOCRINE diseases , *GENETIC disorders - Abstract
Objectives: We tested whether heterozygosity for the K776N mutation (frequency: 0.4%) in ATP-binding cassette transporter A1 (ABCA1) predicted ischemic heart disease (IHD) in the Copenhagen City Heart Study population. Background: In a complex trait like IHD, genetic variation is considered to be conferred by common DNA polymorphisms, although rare mutations may have a larger impact. Tangier disease, a rare high-density lipoprotein cholesterol (HDL-C) deficiency syndrome with IHD, is caused by homozygous ABCA1 mutations. Methods: We analyzed blood samples from a large cohort study of 9,076 Danish individuals followed for 24 years (167,287 person-years), during which 1,033 incident IHD events occurred. The hypothesis was retested in an independent case-control study comparing 562 IHD patients with 3,103 controls. Results: The cumulative incidence of IHD as a function of age was increased in K776N heterozygotes compared with non-carriers (log-rank test: p = 0.005). At the age of 80 years, 48% of heterozygotes and 23% of non-carriers had IHD. Incidence rates in non-carriers and K776N heterozygotes were 61 and 157 per 10,000 person-years. The age-adjusted hazard ratio for IHD in K776N heterozygotes versus non-carriers was 2.4 (95% confidence interval 1.3 to 4.5). Adjusting for HDL-C, or for smoking, diabetes, and hypertension did not change the result, suggesting that genotype predicted risk of IHD beyond that offered by HDL-C, and by other conventional risk factors. Similar trends were obtained in an independent case-control study. Conclusions: Heterozygosity for an ABCA1 mutation (K776N) conferred two- to three-fold risk of IHD in 37 participants in the Copenhagen City Heart study. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
29. Genetic variation in ABCA1 and risk of cardiovascular disease
- Author
-
Frikke-Schmidt, Ruth
- Published
- 2011
- Full Text
- View/download PDF
30. Physical activity in leisure time and at work and risk of dementia: A prospective cohort study of 117,616 individuals.
- Author
-
Juul Rasmussen, Ida, Rasmussen, Katrine Laura, Thomassen, Jesper Q., Nordestgaard, Børge G., Schnohr, Peter, Tybjærg-Hansen, Anne, and Frikke-Schmidt, Ruth
- Subjects
- *
PHYSICAL activity , *LEISURE , *DISEASE risk factors , *CARDIOVASCULAR diseases risk factors , *ALZHEIMER'S disease , *VASCULAR dementia - Abstract
Up to 40% of all dementia cases may be preventable, primarily by treating or acting on well-established cardiovascular risk factors such as diabetes, hypertension, smoking, and physical inactivity. Whether physical inactivity is associated with risk of non-Alzheimer's dementia – a disease influenced by cardiovascular risk factors – and whether a given association differs for physical activity in leisure time and at work remains unknown. We conducted a prospective cohort study including 117,616 individuals from the Copenhagen General Population Study and the Copenhagen City Heart Study with up to 43 years of follow-up. Multifactorially adjusted hazard ratios for low versus high physical activity at leisure time was 1.60 (95% confidence interval 1.40–1.83) for non-Alzheimer's dementia and 0.94 (0.80–1.11) for Alzheimer's disease. Corresponding values for non-Alzheimer's dementia after additional adjustment for physical activity at work or apolipoprotein E (APOE) genotype were 1.60 (1.40–1.83) and 1.82 (1.34–2.15). Multifactorially and APOE adjusted hazard ratios for high versus low physical activity at work were 1.50 (1.10–2.05) for non-Alzheimer's dementia and 1.62 (1.14–2.31) for Alzheimer's disease. When combining the two types of physical activity, physical activity in leisure time had the strongest relationship with risk of non-Alzheimer's dementia. Physical inactivity in leisure time was associated with increased risk of non-Alzheimer's dementia, independent of modifiable risk factors and physical activity at work. The present study thus provides evidence for public health advice on physical activity in leisure time for the vascular part of dementia. [Display omitted] • Prospective study including 117,616 individuals from the general Danish population. • Up to 43 years of follow-up with no losses to follow-up. • Low leisure physical activity associates with high risk of non-Alzheimer's dementia. • Leisure versus work physical activity is superior in predicting risk. • Public health advice on physical activity may prevent non-Alzheimer's dementia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Cardiovascular risk factors and risk of vascular-related dementia in high-risk and low-risk prospective cohort studies.
- Author
-
Rasmussen, Ida Juul, Rasmussen, Katrine, Nordestgaard, Børge, Tybjærg-Hansen, Anne, and Frikke-Schmidt, Ruth
- Published
- 2024
- Full Text
- View/download PDF
32. HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease – Insights from randomized clinical trials and human genetics.
- Author
-
Kjeldsen, Emilie Westerlin, Thomassen, Jesper Qvist, and Frikke-Schmidt, Ruth
- Subjects
- *
HDL cholesterol , *HIGH density lipoproteins , *CHOLESTERYL ester transfer protein , *BLOOD cholesterol , *CARDIOVASCULAR diseases , *HUMAN genetics , *CLINICAL trials - Abstract
Through seven decades the inverse association between HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease (ASCVD) has been observed in case-control and prospective cohort studies. This robust inverse association fuelled the enthusiasm towards development of HDL cholesterol increasing drugs, exemplified by the cholesteryl ester transfer protein (CETP) inhibitor trials and the extended-release niacin HPS2-THRIVE trial. These HDL cholesterol increasing trials were launched without conclusive evidence from human genetics, and despite discrepant species dependent evidence from animal studies. Evidence from human genetics and from randomized clinical trials over the last 13 years now point in the direction that concentrations of HDL cholesterol, do not appear to be a viable future path to target therapeutically for prevention of ASCVD. A likely explanation for the strong observational association between low HDL cholesterol and high ASCVD risk is the concomitant inverse association between HDL cholesterol and atherogenic triglyceride-rich lipoproteins. The purpose of the present review is to bring HDL cholesterol increasing trials into a human genetics context exemplified by candidate gene studies of key players in HDL biogenesis as well as by HDL cholesterol related genome-wide association studies. Graphical abstract summarizing conclusions: Observational epidemiology, randomized clinical trials and human genetics suggesting noncausality between low HDL cholesterol concentrations and increased ASCVD risk. Left upper image: 1. Low HDL cholesterol is associated with increased risk of ASCVD, confirmed in numerous case-control and prospective studies. Right upper image: 2. Genetic evidence from consortia and candidate gene studies have shown that the inverse association between HDL cholesterol concentrations and risk of ASCVD may not be of a causal nature. Left lower image: 3. HDL cholesterol concentration increasing trials have so far not shown to reduce risk of ASCVD. Right lower image: 4. Despite lack of support of a causal role, the HDL cholesterol concentration can be used as a biomarker for ASCVD risk prediction. ASCVD = atherosclerotic cardiovascular disease; HDL = high-density lipoprotein. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Promoter haplotype of a new ABCA1 mutant influences expression of familial hypoalphalipoproteinemia
- Author
-
Slatter, Tania L., Williams, Michael J.A., Frikke-Schmidt, Ruth, Tybjærg-Hansen, Anne, Morison, Ian M., and McCormick, Sally P.A.
- Subjects
- *
GENETIC mutation , *HIGH density lipoproteins , *HYPOLIPOPROTEINEMIA , *PROTEIN binding - Abstract
Abstract: Mutations in the ATP-binding cassette A1 (ABCA1) transporter cause the high-density lipoprotein (HDL) deficiency syndromes of Tangier disease and familial hypoalphalipoproteinemia (FHA). Between individuals carrying ABCA1 mutations, the expression of FHA can be highly variable. Using denaturing HPLC (dHPLC) and direct promoter sequencing we screened the ABCA1 gene of a family with Tangier disease and variable expression of FHA. A new mutation (R1068H) within the first ATP-binding domain was identified in homozygous form in the Tangier disease individual and was present in several family members. Haplotyping of both 1068H alleles in the proband showed homozygosity in the coding region, however, the maternal 1068H allele had three single nucleotide polymorphisms (SNPs) in the promoter previously reported to be associated with reduced ABCA1 expression and HDL levels. An analysis of HDL levels based on 1068H allele haplotype showed the paternal 1068H heterozygotes to have the expected low HDL levels (0.67±0.16mmol/L), while maternal 1068H heterozygotes showed normal HDL levels (1.18±0.14mmol/L). Haplotype analysis of the wildtype allele amongst heterozygotes showed no haplotype that was common to the paternal or maternal side. We propose that the paternal 1068H ABCA1 allele causes a negative effect on the function of the wildtype allele and is associated with low HDL levels. In contrast, the maternal 1068H allele has less effect and is associated with a relatively normal HDL level. We conclude that haplotypes of mutant ABCA1 alleles may contribute to the phenotypic variance shown between FHA individuals. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
34. Modulation of inflammation by treatment with tocilizumab after out-of-hospital cardiac arrest and associations with clinical status, myocardial- and brain injury.
- Author
-
Meyer, Martin Abild Stengaard, Bjerre, Mette, Wiberg, Sebastian, Grand, Johannes, Obling, Laust Emil Roelsgaard, Meyer, Anna Sina Pettersson, Josiassen, Jakob, Frydland, Martin, Thomsen, Jakob Hartvig, Frikke-Schmidt, Ruth, Kjaergaard, Jesper, and Hassager, Christian
- Subjects
- *
BRAIN injuries , *CARDIAC arrest , *TOCILIZUMAB , *LEUKOCYTE count , *MYOCARDIAL injury , *MONOCYTES - Abstract
To investigate how the inflammatory response after out-of-hospital cardiac arrest (OHCA) is modulated by blocking IL-6-mediated signalling with tocilizumab, and to relate induced changes to clinical status, myocardial- and brain injury. This is a preplanned substudy of the IMICA trial (ClinicalTrials.gov , NCT03863015). Upon admission 80 comatose OHCA patients were randomized to infusion of tocilizumab or placebo. Inflammation was characterized by a cytokine assay, CRP, and leukocyte differential count; myocardial injury by TnT and NT-proBNP; brain injury by neuron-specific enolase (NSE) and Neurofilament Light chain (NFL), while sequential organ assessment (SOFA) score and Vasoactive-Inotropic Score (VIS) represented overall clinical status. Responses for IL-5, IL-6, IL-17, neutrophil as well as monocyte counts, and VIS were affected by tocilizumab treatment (all p < 0.05), while there was no effect on levels of NFL. IL-5 and IL-6 were substantially increased by tocilizumab, while IL-17 was lowered. Neutrophils and monocytes were lower at 24 and 48 hours, and VIS was lower at 24 hours, for the tocilizumab group compared to placebo. Multiple correlations were identified for markers of organ injury and clinical status versus inflammatory markers; this included correlations of neutrophils and monocytes with TnT, NSE, NFL, SOFA- and VIS score for the tocilizumab but not the placebo group. NT-proBNP, NFL and SOFA score correlated with CRP in both groups. Treatment with tocilizumab after OHCA modulated the inflammatory response with notable increases for IL-5, IL-6, and decreases for neutrophils and monocytes, as well as reduced vasopressor and inotropy requirements. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population.
- Author
-
Rasmussen, Katrine L., Tybjærg-Hansen, Anne, Nordestgaard, Børge G., and Frikke-Schmidt, Ruth
- Subjects
- *
BLOOD plasma , *ANALYSIS of triglycerides , *APOLIPOPROTEIN E , *CORONARY disease , *DYSLIPIDEMIA , *MYOCARDIAL infarction treatment , *THERAPEUTICS - Abstract
Background and aims Triglyceride-rich lipoproteins are causally associated with high risk of ischemic heart disease (IHD), and apolipoprotein E (apoE) has a central role in their plasma clearance. While both quantitative and qualitative changes of apoE are established causes of rare dyslipidemia syndromes, it remains unclear whether plasma levels of apoE are associated with risk of IHD in the general population. Methods We tested whether plasma levels of apoE at enrollment were associated with future risk of IHD and myocardial infarction (MI) in 91,695 individuals from the general population. Results Multifactorially adjusted hazard ratios (HRs) for highest versus lowest apoE tertile were 1.15 (1.04–1.27) for IHD and 1.16 (1.00–1.36) for MI in men, and 0.94 (0.84–1.05) and 1.04 (0.85–1.26) in women. These associations were attenuated by adjustments for triglyceride levels. Corresponding HRs for highest versus lowest apoE tertile in ε33 carriers were 1.18 (1.03–1.36) for IHD and 1.21 (0.98–1.49) for MI in men, and 0.91 (0.78–1.06) and 0.93 (0.71–1.21) in women. Thus, the present associations were independent of APOE genotype. Conclusion These findings suggest that high plasma levels of apoE are associated with IHD in men but not in women. Triglyceride-rich lipoproteins may partly explain these associations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- Author
-
Varbo, Anette, Benn, Marianne, Tybjærg-Hansen, Anne, Jørgensen, Anders B., Frikke-Schmidt, Ruth, and Nordestgaard, Børge G.
- Subjects
- *
CORONARY heart disease risk factors , *CHOLESTEROL , *HIGH density lipoproteins , *TRIGLYCERIDES , *RANDOMIZATION (Statistics) , *CONFIDENCE intervals - Abstract
Objectives: The aim of this study was to test the hypothesis that elevated nonfasting remnant cholesterol is a causal risk factor for ischemic heart disease independent of reduced high-density lipoprotein (HDL) cholesterol. Background: Elevated remnant cholesterol is associated with elevated levels of triglyceride-rich lipoproteins and with reduced HDL cholesterol, and all are associated with ischemic heart disease. Methods: A total of 73,513 subjects from Copenhagen were genotyped, of whom 11,984 had ischemic heart disease diagnosed between 1976 and 2010. Fifteen genetic variants were selected, affecting: 1) nonfasting remnant cholesterol alone; 2) nonfasting remnant cholesterol and HDL cholesterol combined; 3) HDL cholesterol alone; or 4) low-density lipoprotein (LDL) cholesterol alone as a positive control. The variants were used in a Mendelian randomization design. Results: The causal odds ratio for a 1 mmol/l (39 mg/dl) genetic increase of nonfasting remnant cholesterol was 2.8 (95% confidence interval [CI]: 1.9 to 4.2), with a corresponding observational hazard ratio of 1.4 (95% CI: 1.3 to 1.5). For the ratio of nonfasting remnant cholesterol to HDL cholesterol, corresponding values were 2.9 (95% CI: 1.9 to 4.6) causal and 1.2 (95% CI 1.2 to 1.3) observational for a 1-U increase. However, for HDL cholesterol, corresponding values were 0.7 (95% CI: 0.4 to 1.4) causal and 1.6 (95% CI: 1.4 to 1.7) observational for a 1 mmol/l (39 mg/dl) decrease. Finally, for LDL cholesterol, corresponding values were 1.5 (95% CI: 1.3 to 1.6) causal and 1.1 (95% CI: 1.1 to 1.2) observational for a 1 mmol/l (39 mg/dl) increase. Conclusions: A nonfasting remnant cholesterol increase of 1 mmol/l (39 mg/dl) is associated with a 2.8-fold causal risk for ischemic heart disease, independent of reduced HDL cholesterol. This implies that elevated cholesterol content of triglyceride-rich lipoprotein particles causes ischemic heart disease. However, because pleiotropic effects of the genetic variants studied cannot be totally excluded, these findings need to be confirmed using additional genetic variants and/or randomized intervention trials. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
37. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism
- Author
-
Karuna, Ratna, Holleboom, Adriaan G., Motazacker, Mohammad M., Kuivenhoven, Jan Albert, Frikke-Schmidt, Ruth, Tybjaerg-Hansen, Anne, Georgopoulos, Spiros, van Eck, Miranda, van Berkel, Theo J.C., von Eckardstein, Arnold, and Rentsch, Katharina M.
- Subjects
- *
CHOLESTEROL , *BLOOD plasma , *HIGH density lipoproteins , *MASS spectrometry , *OXYSTEROLS , *ACYLTRANSFERASES , *LABORATORY mice ,BLOOD lipoprotein metabolism - Abstract
Abstract: Secretion of 27-hydroxycholesterol (27OHC) from macrophages is considered as an alternative to HDL-mediated reverse transport of excess cholesterol. We investigated 27OHC-concentrations in plasma of humans and mice with monogenic disorders of HDL metabolism. As compared to family controls mutations in the genes for apolipoprotein A-I, ATP binding cassette transporter (ABC) A1 and lecithin:cholesterol acylstransferase (LCAT) were associated with reduced concentrations of both HDL-cholesterol and HDL-27OHC whereas mutations in the genes for cholesterylester transfer protein (CETP), scavenger receptor type BI and hepatic lipase were associated with elevated HDL concentrations of either sterol. Compared to family controls and relative to the concentrations of total 27OHC and cholesterol, lower 27OHC-ester but normal cholesterylester levels were found in HDL of heterozygous LCAT mutation carriers and nonHDL of heterozygous CETP mutation carriers. In family controls, LCAT activity and CETP mass were more strongly correlated with 27OHC-ester than cholesterylester concentrations in HDL and nonHDL, respectively. These findings suggest that the formation and transfer of 27OHC-esters are more sensitive to reduced activities of LCAT and CETP, respectively, than the formation and transfer of cholesterylesters. 27OHC plasma levels were also decreased in apoA-I-, ABCA1- or LCAT-knockout mice but increased in SR-BI-knockout mice. Transplantation of ABCA1- and/or ABCG1-deficient bone marrow into LDL receptor deficient mice decreased plasma levels of 27OHC. In conclusion, mutations or absence of HDL genes lead to distinct alterations in the quantity, esterification or lipoprotein distribution of 27OHC. These findings argue against the earlier suggestion that 27OHC-metabolism in plasma occurs independently of HDL. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
38. Response: Lipoprotein Subclass Profiling Reveals Pleiotropy in the Genetic Variants of Lipid Risk Factors for Coronary Heart Disease: A Note on Mendelian Randomization Studies.
- Author
-
Varbo, Anette, Benn, Marianne, Tybjærg-Hansen, Anne, Jørgensen, Anders B., Frikke-Schmidt, Ruth, and Nordestgaard, Børge G.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.